Morgan Stanley analyst Terence Flynn lowered the firm’s price target on Moderna (MRNA) to $38 from $70 and keeps an Equal Weight rating on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback